<SUBMISSION>
<ACCESSION-NUMBER>0000950133-05-004796
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051026
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20051031
<DATE-OF-FILING-DATE-CHANGE>20051031
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>051166446
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
<PHONE>4849131200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w14068e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>



<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>PURSUANT TO SECTION 13 OR 15 (d)&nbsp;OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Date of
Report (Date of earliest event reported): October&nbsp;26, 2005
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">NOVAVAX, INC.</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact Name of Registrant as Specified in Charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><U><B>DELAWARE</B></U><BR>
(State or Other Jurisdiction<BR>
of
Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><u><B>0-26770</B></U><BR>
(Commission File Number)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->

<TR valign="bottom">
    <TD align="center" valign="top"><B>508 Lapp
Road,</B><BR><U><b>Malvern, Pennsylvania</b></U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><u><B>19355</B></U></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(Zip Code)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><BR>
</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000"> </FONT></DIV></DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>484-913-1200</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000"> Registrant&#146;s telephone number, including area code: </FONT></DIV></DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>N/A</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000"> (Former Name or Former Address, if Changed Since Last Report)</FONT></DIV></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link2 "Item&nbsp;8.01 Other Events" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Item&nbsp;8.01 Other Events
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax,
Inc. (&#147;Novavax&#148;) issued a press release on October&nbsp;26, 2005 announcing that certain
holders of $6.0&nbsp;million face amount of Novavax&#146;s 4.75% senior convertible notes due July&nbsp;15, 2009
(the &#147;Notes&#148;) exercised their optional conversion right to convert such Notes. A copy of the press
release dated October&nbsp;26, 2005 is being filed as Exhibit&nbsp;99.1 to this Current Report on Form 8-K.
</DIV>

<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Item&nbsp;9.01 Financial Statements and Exhibits.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;Exhibits.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">99.1
&#151; Press release issued by Novavax dated October&nbsp;26, 2005.

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SIGNATURES
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">NOVAVAX, INC. <BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">/s/ Dennis W. Genge
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Dennis W. Genge&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Vice President and Chief<BR>
Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">October&nbsp;31, 2005

</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "EXHIBIT INDEX" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT INDEX
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following exhibit is filed herewith:

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><U>Exhibit No.</U></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><U>Description</U></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release issued by Novavax,
Inc. (&#147;Novavax&#148;) on October&nbsp;26, 2005 announcing that
announcing that certain holders of $6.0&nbsp;million face amount of Novavax&#146;s 4.75% senior
convertible notes due July&nbsp;15, 2009 (the &#147;Notes&#148;) exercised their optional conversion right to
convert such Notes.</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w14068exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="w14068w1406801.gif" alt="(NOVAVAX INC. LOGO)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B>FOR IMMEDIATE RELEASE</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>NASDAQ symbol: NVAX</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOVAVAX BOND HOLDERS ELECT TO<BR>
CONVERT $6 MILLION OF OUTSTANDING NOTES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>MALVERN, PA., October&nbsp;26, 2005 &#151;  Novavax, Inc. (Nasdaq: NVAX) </B>announced today that
certain holders of $6.0&nbsp;million face amount of the company&#146;s 4.75% senior convertible notes due
July&nbsp;15, 2009 (the &#147;Notes&#148;) exercised their optional conversion right to convert such Notes into
1,056,338 shares of Novavax Common Stock at the per share conversion price of $5.68. As a result
of the conversion, the aggregate principal amount of Notes outstanding will be reduced from $35.0
million to $29.0&nbsp;million and the company&#146;s stockholders equity will be increased by the same
amount. In addition, the company&#146;s annual interest expense will be reduced by $285,000. With this
conversion, the total outstanding shares of Novavax increases to 44,910,214.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Novavax, Inc.</B><BR>
Novavax, Inc. is a product development company focused on the research, development and
commercialization of products utilizing its proprietary drug delivery and biological technologies
for large and growing markets. Novavax&#146;s drug delivery technologies include the Micellar
Nanoparticle (MNP)&nbsp;technology which is the basis for the development of its first FDA approved
product, Estrasorb. In addition to MNP, Novavax drug delivery technologies include Novasomes
(paucillamellar non-phospholipid liposomes) and Sterisome technologies. Novavax&#146;s vaccine
technologies include virus like particle manufacturing technology utilizing the baculovirus
expression system in insect cells as well as novel vaccine adjuvants based on novasomes and
dendrimer technologies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Statements made in this press release that state Novavax&#146;s or management&#146;s intentions, hopes,
beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking
statements include but are not limited to statements regarding usage of cash, product sales, future
product development and related clinical trials and future research and development, including FDA
approval. Novavax&#146;s actual results could differ materially from those expressed in such
forward-looking statements. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results, performance or achievements of
the Company, or industry results, to be materially different from those expressed or implied by
such forward-looking statements. Such factors include, among other things, the following: general
economic and business conditions; ability to enter into future collaborations with industry
partners, including an ESTRASORB<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> licensing agreement; competition; unexpected
changes in technologies and technological advances; ability to obtain rights to technology; ability
to obtain and enforce patents; ability to commercialize and manufacture products; ability to
establish and maintain commercial-scale manufacturing capabilities; results of clinical studies;
progress of research and development activities; business abilities and judgment of personnel;
availability of qualified personnel; changes in, or failure to comply with, governmental
regulations; the ability to obtain adequate financing in the future through product licensing,
co-promotional arrangements, public or private equity financing or otherwise; and other factors
referenced herein. Additional information is contained in Novavax&#146;s annual report on Form&nbsp;10K for
the year ended December&nbsp;31, 2004 and quarterly reports on Form&nbsp;10Q for the quarters ended March&nbsp;31,
2005 and June&nbsp;30, 2005, incorporated herein by reference. Statements made herein should be read in
conjunction with Novavax&#146;s annual and quarterly reports filed with the SEC. Copies of these filings
may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the
SEC at <U>www.sec.gov</U>.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">- ### -
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For Further Information Contact:<BR>
Investor Relations<BR>
Kathy Hamilton<BR>
Novavax, Inc.<BR>
Tel: (484)&nbsp;913-1213<BR>
<B>Email: </B><U><B>KHamilton@novavax.com</B></U>

</DIV>


<P align="center" style="font-size: 10pt">
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w14068w1406801.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w14068w1406801.gif
M1TE&.#=A(`%*`/<``````(````"``("`````@(``@`"`@,#`P,#<P*;*\$`@
M`&`@`(`@`*`@`,`@`.`@``!``"!``$!``&!``(!``*!``,!``.!```!@`"!@
M`$!@`&!@`(!@`*!@`,!@`.!@``"``""``$"``&"``("``*"``,"``."```"@
M`""@`$"@`&"@`("@`*"@`,"@`."@``#``"#``$#``&#``(#``*#``,#``.#`
M``#@`"#@`$#@`&#@`(#@`*#@`,#@`.#@````0"``0$``0&``0(``0*``0,``
M0.``0``@0"`@0$`@0&`@0(`@0*`@0,`@0.`@0`!`0"!`0$!`0&!`0(!`0*!`
M0,!`0.!`0`!@0"!@0$!@0&!@0(!@0*!@0,!@0.!@0`"`0""`0$"`0&"`0("`
M0*"`0,"`0."`0`"@0""@0$"@0&"@0("@0*"@0,"@0."@0`#`0"#`0$#`0&#`
M0(#`0*#`0,#`0.#`0`#@0"#@0$#@0&#@0(#@0*#@0,#@0.#@0```@"``@$``
M@&``@(``@*``@,``@.``@``@@"`@@$`@@&`@@(`@@*`@@,`@@.`@@`!`@"!`
M@$!`@&!`@(!`@*!`@,!`@.!`@`!@@"!@@$!@@&!@@(!@@*!@@,!@@.!@@`"`
M@""`@$"`@&"`@("`@*"`@,"`@."`@`"@@""@@$"@@&"@@("@@*"@@,"@@."@
M@`#`@"#`@$#`@&#`@(#`@*#`@,#`@.#`@`#@@"#@@$#@@&#@@(#@@*#@@,#@
M@.#@@```P"``P$``P&``P(``P*``P,``P.``P``@P"`@P$`@P&`@P(`@P*`@
MP,`@P.`@P`!`P"!`P$!`P&!`P(!`P*!`P,!`P.!`P`!@P"!@P$!@P&!@P(!@
MP*!@P,!@P.!@P`"`P""`P$"`P&"`P("`P*"`P,"`P."`P`"@P""@P$"@P&"@
MP("@P*"@P,"@P."@P`#`P"#`P$#`P&#`P(#`P*#`P/_[\*"@I("`@/\```#_
M`/__````__\`_P#______R'Y!```````+``````@`4H```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K
M6+-JW<JUZT1[8+V*/8D@@=FS!\XB:&BO'H*T:B&V7:7*`*:[=O$:4#5O+4-[
M9N&>3>!7;MG`:!<"3G"@<>.S]OY%1BAX<()Z$]&F38MY85G'EA,@;!MZL,/#
MB#E/WFC7@&O7>C&)7E@/4VO8JQS64V7[M>_?L#&IFHT00>_?=R7..OX:4VZ%
MS)$_3WA7;_/"#A,PQXN)MNWHKE4E_UP%'O:]O^63=ZP+_#?#`^WG,9Q7OGU[
M3)HZ'V0/7'9$^YBL=E`]]C5'W(`%3N?0*O;IAU"!L!U8$'_]26@0A`)J1*%]
M\BF40'P>0B@B<N(=A$"!)9Y67HH/CJC@0?5U!U%ZM(W(XH40*L3@?19FM.%]
M&19T`'@=#EC?B`4&^4^!,CKTHUW8&43@B/Z-5Z"#WK7WXD"3(8E)E`1IER!"
MM=V'Y49/`G=C06+^5F1!92(I)VQ!3MG>F0G9ITE"D<VY)4'VU+=F0D\V:5!D
M\\@YZ$!Q]G=FH/;-$E*:R.$I4)N^O3F0<2(*5\^GEZW#VX@PVK>HE`TJE*B<
M52*49H!LK?^XT)'(@4E0H\A)F.:I/LZ9$*:O:2I0IY9*1AZ$6^[8GY(&I3EK
MA;+^6E^QM_*HD)W-[=8>K_\HVUZU[>TI$J7`_?D/L*X)BZV:#:'K&ZR2"00I
MB(J5)Q^SLVS[3Z$]#K1K0Z8^B]P_Z\)F*T&4/C?OP".1BYR2[@H+H;C,RGON
MD5M2RI"WS47&+'C^<<IN0@5'N)"[!E"[JIO#ZBNPHTM:V_"=T;))I,T`'HP0
MQ^X5)'*M?,8\\LXN"YTK=!PNQ+-=+S<WT#KV]3L0RJXMC0FU:'Y;Z)D1%[1T
M>!+%"&::Y@J$J\%('VUVS0=];4#3KY7]3[[E<LDVF;367=*3DM7_9U#7!&ER
MI424GGGV:PH]R>O2-^;,9WU2EPPO0B`?:+7.`]&GZ$E\_[/R;R\"/E",%2?T
M.>BEWHD0RL5^V-\!<`9LI9:$%GW0Z6`3]+-OW`KD=L\F=6[TNP>*WG>!F:%X
MN^RH?CO[;X,Z7ASR!RUL8-K$`[KO?9@/)#B$D^_M_,6VN\XRESE*="+S@-:G
MY)/"V@VS070/O5^J!C$^6K>V,\J^0B(23>G6,[[MS>]<])+7D9+W/W_A3W<@
MJ]C2Q'6H].BL9'LYB)FP=ST-RNQ:(LK-`#DBO./U9R#P`<Z;K`<\B*RO?U.[
M&__T=A!W7>UYT..@TW#&,*+9+W8PY"&3_[!&0.#`J3S/2>'Y%`B@B6`P@Z[Z
MH$!`IC-G/>X^L$,([ER#I2?)#6342H_46`@@J7FDA"WKSUJ,]X\8F5&+8R)3
MTOSW0PBJ+G$-E!<9H3@0(.'0-PO9(A^;-2=#S<R(/O.;$C,UH<%93#$&O&.+
M@$/!2&:K=G/RDM2L)D""T6XT><ND768CH-\%\2-H]%V#7LA(@KBM=T($6D+J
M]RZ_D-&0=A2EC1*RN[@Y4)9MT^4NC[@MM\DM:XCDDF0`5#)-];*#3DK?%?6V
MQ?@)Q&'"'"4F&>:N4^TQF]`DW[*&]RXB8B25:YN3L+YGGX<<SI=*NT\:WR4M
M<(KH5(?SS]**96Q*<*9HCS<49X4.V<)&RDE=$QOA.^G$$%;Z!@$.K5KU+&E/
M*1;$/KEI)R@KRJ0NL6^A!ABA1=`ID&?.L2#LO(\U)3.J`IVG(8J#FMJ:=Y_F
MM.8[>>G-`N'8'O.U,I@U#4YUJI,7V`3L5834D_;_2%C`_!VTAGD3SBH^58]Y
M,"AOL#3;G$Z5TAU"!(,!K2"K*B;#&IFJC![$Z*2::I!0&L":5*OH?[QDJ7<>
M<Y)L'4@_<P?4F3Y$E^8RJ5W,.1&2,BJ4*P6I,"OI$$$FTR!=9:A$'&NIN(:S
M(&5ER!/#I2JQH3*O!H60-2.3`&QZZ:Z4&U%=,PLPZA4D,M@\%2?C-5<O#9!2
MX=,0:,.4-TF9-9O">:...L4LM%+D:V$E)H0JR]J-T;4A1\HJ1#0QU.HTA#S5
MK2YJ_X$`WKC5+IJ8A4@]])WLWL5<V,VN=*&J4Z%2Q[Q#)51YATK8ZG$'OL)1
M41PW`ABP^%>XE_*O@`4<^9'+T"6G>%&%*J8*8(<,^,%\2H"`)2SABRQ&P@)&
M`+,P_&"P2.TP$^Y>0\VBX0<3!B*T!$Y]Q\+BHN!6Q"V.,5%H-5X9VQ@E#,+,
MCNJ2WW/QV#F7BNZ-ARP3!LEGQ[#!3&\6K!^9WF>[1([R1XP\0P2F;$H"F@QN
M5RSE+F.$RCL"#!>GM%'C>OG,(0&S:\2<LC:.^2T+3F>!&HSF.D.$-[FY:EON
M@ID/56>J^-%K=G/*6#L;NB((J$=D$HV9MBAZ:I]:BX8/36F6A*72F,ZTIC?-
JZ4Y[^M.@#K6H1TWJ4IOZU*A.M:I7S>I6N_K5L(ZUK&=-ZUK;^M8!`0`[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
